
    
      Following screening for eligibility, women will be studied at baseline and then randomized to
      one of two groups:

      Group A administered Femoston Conti - oral oestradiol 17β 0.5 mg/dydrogesterone 2.5 mg daily
      for the duration of the treatment phase (24 weeks)

      Group B administered ½ Evorel Conti patches - trans-dermal Estradiol 25 mcg/norethisterone
      acetate 85 mcg (½ Evorel Conti patches) daily for the duration of the treatment phase (24
      weeks).

      Studies will be repeated after 6 months of therapy at the follow up visit.
    
  